A notable advantage of SGLT2 inhibitors is their minimal risk of inducing hypoglycemia
Such off-label use, i.e., made in the absence of an FDA approval for this indication, in itself is reason for carefully conducted, evidence-based clinical trials, say the researchers, who reported results in JAMA Psychiatry
In the early DM group, there was no difference in total cholesterol and triglyceride levels among the three groups (Fig
There are no widely reported direct, significant drug-drug interactions that would contraindicate their concurrent use
Bias against GLP-1s is bigger than stigmaits a systemic risk leaders cant afford to ignore
Second, baselines and potential confounders were adjusted to create a robust control group